Cancer: A Role for Nutritional Supplements

[Guest guest]

Cancer: A Role for Nutritional Supplements JoAnn Guest Jun 24, 2005 10:39

PDT

http://www.willner.com/article.aspx?artid=105

 

Cancer

by Kim Schoenhals

 

Cancer is one of the leading causes of death in America, second only to

heart disease. There were approximately 553,400 cancer deaths in

2001--more than 1,500 people per day--according to the American Cancer

Society (ACS) (www.cancer.org).

 

ACS also estimated the total number of newly diagnosed U.S. cancer cases

in 2001 was 1,268,000, excluding basal and squamous cell skin

cancers--of which more than 1 million cases were

diagnosed on 2001--and in situ (noninvasive cancer) carcinomas, except

urinary bladder. Lung cancer is the leading cause of cancer death in the

United States (there were 157,400 lung cancer deaths in 2001), followed

by colorectal cancer (56,700), breast cancer (40,600) and prostate

cancer (31,500).

 

The single most important risk factor for cancer is age, according to

the National Institutes of Health (NIH). Aside from age, smoking status

and alcohol intake are telling signs of cancer risk.

 

Approximately 172,000 cancer deaths were caused by tobacco use in 2001,

and about 19,000 cancer deaths may have been related to excessive

alcohol use, according to ACS.

 

Obesity also increases the risk of certain cancers.

The relative risk of breast cancer increases by 50 percent in obese

women, and the risk of colon cancer increases 40 percent in obese men.

 

For those Americans who do not use tobacco, dietary choices and physical

activity become the most important modifiable determinants of cancer

risk.

 

More than a dozen food-derived agents are currently being studied

for their application in cancer prevention, according to James Crowell,

Ph.D., who--with his colleagues at the National Cancer Institute

(NCI)--presented a symposium as part of the Experimental Biology meeting

in Washington, D.C., April 17 to 21, 1999, on the progress of cancer

chemoprevention and the development of diet-derived chemopreventive

agents.1

 

Some compounds for which NCI is funding academic research

include green and black tea polyphenols, soy isoflavones, vitamin D,

vitamin E, selenium, calcium and indole-3-carbinol.

 

" Many pharmacologically active compounds will come out of foods, "

Crowell said. " Because the food industry has not typically had

experience in doing this type of research, I think the government has a

good part to play. ... It's important that some of these [food-derived

agents] be investigated in a thorough and systematic scientific way, as

you would for a drug. "

 

Because a poor diet is a significant risk factor for cancer development,

vitamin and mineral intake is also closely correlated with reducing the

risk of cancer.

 

Aside from vitamin and mineral supplements, various carotenoids,

botanicals and essential fatty acids may have roles in the prevention of

cancer.

 

Vitamins and Minerals

 

Vitamins and minerals are among the most often studied supplements on

the market and the most popular with consumers.

Cancer patients are more likely than the general population to turn to

alternative remedies for adjuvant support.

 

According to the Natural Marketing Institute's Health & Wellness Trends

Database--three years of trended data including more than 2,000 consumer

household respondents--71.1 percent of consumers who

have cancer use multivitamin and multimineral supplements compared to

66.8 percent of the general population.

 

In addition, cancer patients are more likely to believe in the benefits

of multivitamin and mineral supplements than the general population.

 

While 33 percent of the general population " agrees completely " that

vitamins and minerals are beneficial in the prevention of certain health

conditions, 38.9 percent of cancer patients say the same, according to

NMI.

 

One of the most well known bunch of vitamins and minerals are

antioxidants.

 

With their free radical fighting skills, antioxidants

protect the body from oxidative damage, which is considered a major

factor in cancer development.

 

One antioxidant all-star is vitamin E. According to NMI, 58.4 percent of

consumers who have cancer supplement

their diet with vitamin E as compared to 45.7 percent of the general

population.

 

Vitamin E supplements usually contain alpha-tocopherol,

although there are eight potentially beneficial isomers of vitamin E:

alpha-, beta-, delta- and gamma-tocopherol, as well as alpha-, beta-,

delta- and gamma-tocotrienol.

 

Researchers from NCI evaluated data from the Alpha-Tocopherol,

Beta-Carotene Cancer Prevention Study and discovered that daily

supplementation with alpha-tocopherol reduced prostate cancer risk in a

large, randomized cohort.2 Additional research conducted by scientists

from the University of Rochester determined the mechanism of action

behind alpha-tocopherol's anti-carcinogenic properties could be its

suppression of prostate-specific antigen (PSA), a marker for the

progression of prostate cancer, as well as its inhibition of the growth

of prostate cancer cells in vitro.3

 

Vitamin E has also been suggested to prevent gastric cancer, according

to researchers at Jagiellonian University in Cracow, Poland.

 

In reviewing 180 colorectal cancer and 80 gastric cancer cases,

researchers concluded there was an inverse correlation between vitamin E

and gastric cancer.4

 

One researcher from the Wake Forest University School of Medicine in

Winston-Salem, N.C., conducted a research review and concluded the

modest protection from breast cancer associated with dietary vitamin E

may be due to the effects of the other tocopherols and tocotrienols in

the diet, not just alpha-tocopherol.

 

The researcher cited several studies in which vitamin E supplements

protected against breast cancer.

 

Specifically, alpha-, gamma- and delta-tocotrienol, as well as

delta-tocopherol, reduced the growth and enhanced the death of cancer

cells, which may reduce the risk of breast cancer.5

 

The tocotrienol mixture from palm oil was also determined to inhibit

several lines of breast cancer cells, according to in vitro research

conducted at the Palm Oil Research Institute of Malaysia in Kuala

Lumpur.6

 

Another antioxidant vitamin, vitamin C, is commonly studied for its

effects in cancer prevention. NMI noted that while 45.4 percent of the

general population uses vitamin C supplements, 55.7 percent of cancer

patients take them.

 

Vitamin C has been linked with reducing the risk of gastric and

esophageal cancer by joint research out of Yale University's

School of Medicine, NCI and other institutions.

 

Their research was a three-region, case-controlled study involving

1,095 Americans diagnosed with cancer of the esophagus or stomach and

687 healthy controls.

 

Vitamin C use was defined as taking a supplement at least once a week

for a minimum period of six months.7

 

" Our study suggests that taking a vitamin C supplement on a regular

basis may protect against certain types of stomach cancer, " said Susan

T. Mayne, an associate professor at Yale University School of Medicine

and lead investigator of the study,

in a press release from the Dietary Supplement Information Bureau™ and

IMAGINutrition Inc. " We found vitamin C supplement users to have a 40

percent lower risk of cancer in the middle and lower parts of the

stomach. "

 

 

Another compound with antioxidant properties is coenzyme Q10

 

(CoQ10), which is essential to cellular energy production. According to

research out of Purdue University in West Lafayette, Ind., CoQ10

deficiency is commonly found in cancer cases.8

 

Researchers from the Medical School of Osmangazi University in

Eskisehir, Turkey, found similar results.

 

A group of 21 breast cancer patients who had undergone radical

mastectomy exhibited significantly decreased CoQ10 concentrations in

tumor tissues as compared to the surrounding normal tissues. Researchers

concluded that supplementation with CoQ10 might induce protective

effects on breast tissue.9

 

 

In addition to antioxidant vitamins, the B vitamins are purportedly

useful against cancer.

 

Compared to 24 percent of the general population, 27.8 percent of those

fighting cancer take a B complex, according to NMI. In addition, NMI

noted that 19.1 percent of cancer patients take

folic acid, compared to 14.6 percent of the general population.

 

Folic acid is especially protective during pregnancy, according to

research out of the Cancer Foundation of Western Australia in West

Perth.

Women who took folate supplements during pregnancy gave birth to

children with reduced risk of developing acute lymphoblastic leukemia.10

 

 

 

Folic acid may also have protective effects against gastric cancer, as

demonstrated by animal research conducted at the Shanghai Second Medical

University in China. They fed 16 male dogs a chemical carcinogen for 15

months. Half of the dogs also received 20 mg/d of folic acid. All

animals in the control group and only three of eight animals in the

folate group developed cancer.11

 

Human research conducted at the Albert Einstein College of Medicine in

Bronx, N.Y., indicated that folic acid intake may reduce the risk of

colorectal cancer.

 

Researchers reviewed a total of 56,837 female cases from the Canadian

National Breast Screening Study, of which 389 cases of

colorectal cancer were diagnosed during follow-up. A subcohort of 5,681

women was randomly selected at baseline.

 

The final analysis, which was based on 295 cases and 5,334 controls,

indicated that the women with the highest intakes of folic acid were the

least likely to develop colorectal cancer.12

 

Research out of Tufts University in Boston demonstrated that in addition

to folic acid, vitamins B2, B6 and B12 are involved in cancer prevention

 

because they are the source of coenzymes that participate in one carbon

metabolism, a metabolic process that affects DNA.

 

According to

researchers, cancer may be partially explained by inadequate intake of

these vitamins.13

 

Vitamin B6 may also offer specific protection against cancer, as

indicated by recent animal research out of Hiroshima University in

Japan. Researchers fed mice one of four diets (1 mg/kg, 7 mg/kg, 14

mg/kg or 35 mg/kg of vitamin B6) for 22 weeks, and the mice were given a

 

weekly injection of azoxymethane to induce cancer. The 7 mg/kg, 14 mg/kg

 

and 35 mg/kg diets significantly suppressed the incidence and number of

colon tumors, leading the researchers to conclude that vitamin B6

suppresses colon cancer by reducing cell proliferation.14

 

Vitamin D is another vitamin that may have some clout in the fight

against cancer. Specifically, it is believed to protect against colon

cancer, according to animal research conducted by David J. Mangelsdorf,

Ph.D., and investigators from the Howard Hughes Medical Institute, based

 

in Chevy Chase, Md., who were studying the mechanism of action behind

vitamin D's protective effects. Vitamin D helps the body detoxify

lithocholic acid, a secondary bile acid created in the intestine during

the digestion of fat, which has been shown to cause colon cancer in lab

animals. However, when the lab animals were given concurrent high doses

of vitamin D, they did not develop colon cancer.15 " Vitamin D is not a

therapy for colon cancer, " Mangelsdorf said. " It prevents it. That's why

 

it's important to already have in your diet an adequate supply of

vitamin D. ... But you have to be careful because vitamin D is toxic at

high concentrations. "

 

In addition to vitamins, minerals are a hot topic in the realm of cancer

 

prevention. Selenium has been on the forefront of current research,

especially in regard to prostate cancer. NCI is at present conducting a

10-year trial to determine the efficacy of vitamin E and selenium for

preventing cancer of the prostate. Independently, low plasma levels of

selenium have been associated with a four- to five-fold increase in the

risk of prostate cancer, according to researchers from the Stanford

University Medical Center in Stanford, Calif.16 Selenium (as

SelenoExcell®, manufactured by Fresno, Calif.-based Cypress Systems) is

being studied in several other NCI-funded clinical trials at Tucson's

University of Arizona Cancer Center to determine the mineral's role in

reducing the risk of prostate cancer.

 

Low serum selenium levels are also indicated in the risk of developing

esophageal and gastric cancers, according NCI research. Investigators

based a new study on a previous nutritional intervention

trial--conducted in Linxian, China, where gastric and esophageal cancers

 

are at epidemic rates--that determined supplementation with selenium, as

 

well as beta-carotene and vitamin E, significantly lowered cancer

mortality rates. Researchers measured serum selenium levels in 590

subjects with esophageal cancer, 402 with gastric cardia cancer and 87

with gastric non-cardia cancer, as well as 1,062 control subjects.

Researchers found a highly significant inverse association between serum

 

selenium levels with the incidence of esophageal and gastric cardia

cancers, and concluded selenium levels affect the incidence of certain

cancers.17

 

Another study conducted in Japan determined that selenium, as well as

zinc, may protect against gastric carcinoma. Researchers from the

Hirosaki University School of Medicine investigated the link between

ingestion of trace elements and gastric carcinogenesis because mortality

 

from gastric cancer in Japan is among the highest in the world. Their

findings demonstrated a protective effect from selenium and zinc against

 

the development of gastric cancer.18

 

Low serum concentrations of zinc, chromium and iron may be indicators

for cancer risk, according to animal research conducted at Colorado

State University in Fort Collins. Researchers compared 102 canine cancer

 

cases with control animals and discovered the ailing animals exhibited

mineral abnormalities--specifically, low concentrations of zinc,

chromium and iron.19

 

Calcium is another mineral that has been indicated in cancer nutrition

and is popular among consumers. According to NMI, 50.6 percent of the

general population takes calcium supplements, while 59.6 percent of

cancer patients supplement their diet with the mineral. Higher calcium

intake may reduce the risk of colon cancer, according to researchers at

the Harvard School of Public Health. Their study--involving 87,998

female cases from the Nurse's Health Study and 47,344 male cases from

the Health Professionals Follow-up Study--demonstrated that consuming

700 mg/d to 1,250 mg/d of calcium may reduce the risk of developing

distal colon cancer in both men and women.20

 

In opposition to these findings, a different group of researchers from

the Harvard School of Public Health concluded that men with diets high

in dairy calcium may be at an increased risk for developing prostate

cancer. Researchers investigated the association between dairy products,

 

calcium intake and prostate cancer risk as part of the Physician's

Health Study, a cohort of 20,885 male physicians. Compared with men

consuming 0.5 daily servings of dairy products (150 mg/d), those

consuming greater than 2.5 servings (more than 600 mg/d) had a

32-percent higher risk of prostate cancer.21

 

Mushrooms, Soy and Carotenoids

 

In addition to vitamin and mineral supplements, extracts taken from

foods--such as medicinal mushrooms and vegetables--may also be effective

 

in the fight to prevent cancer. Beta glucan, a polysaccharide of the

Maitake mushroom, has been the topic of recent cancer trials.

Researchers from New York Medical College in Valhalla explored the

anti-carcinogenic potential of beta glucan using human prostate cancer

cells in vitro. Researchers noted 95 percent cell death within 24 hours

when treated with beta glucan (as Grifron-D®, manufactured by Paramus,

N.J.-based Maitake Products).22

 

Aside from Maitake, Agaricus blazei (Himematsutake) is another variety

of mushroom purported to have anti-carcinogenic potential. Research

conducted with Agaricus blazei extract (provided by Los Angeles-based

Atlas World USA) indicated that it can topically and orally prevent

lesions associated with skin cancer, as well as inhibit the growth of

various human tumor cell lines in vitro. Research out of the

Universidade Estadual de Londrina in Brazil indicated that in addition

to possessing anti-carcinogenic potential, an extract of Agaricus blazei

 

exhibited antimutagenic effects in vitro. Researchers evaluated the

effects of the extract on Chinese hamster V79 cells under three

temperatures and concluded that the mushroom was not mutagenic itself,

and it was an efficient antimutagen in all concentrations and

preparations tested.23

 

The active components of Agaricus blazei are believed to be its

polysaccharides, beta 1,3-glucan and beta 1,6-glucan. These beta glucans

 

are thought to stimulate immune activity, specifically the T-cell

subsets, thereby inhibiting tumor formation.24

 

Reishi (Ganoderma lucidum or Mannentake) is another medicinal mushroom

believed to have application in the realm of cancer prevention.

Researchers from Hiroshima University studied the modifying effects of a

 

water-soluble extract from Reishi on the development of aberrations in

the colons of male rats. They found that Reishi both inhibited cell

proliferation in vitro, as well as inhibited anchorage-independent

growth of several colon carcinoma cell lines. Scientists concluded that

Reishi could act as a preventive agent for colon cancer.25

 

A derivation of medicinal mushrooms, AHCC (Active Hexose Correlated

Compound), has also been studied in anti-carcinogenic applications.

(Editor's note: Amino Up Chemical Co. in Sopporo, Japan, owns the

trademark for AHCC and Purchase, N.Y.-based Maypro Industries

distributes the raw material.) AHCC, a hybridization of several species

of medicinal mushrooms, may have synergistic effects with aglycone

isoflavones, or genistein combined polysaccharide (GCP), against

prostate and other cancers, according to a poster presentation given by

Amino Up Chemical researchers at the American Association for Cancer

Research conference in New Orleans on March 26 and 27. Researchers

conducted in vitro research on six human cancer cell lines and two mouse

 

cancer cell lines, with four derived from the prostate, and one each

from the bladder, bone, lung and colon. Both GCP and GCP plus AHCC

treatments inhibited the growth of all cell lines in a dose-dependent

manner, while AHCC did not show obvious inhibiting effects except on the

 

colon cancer cell line.

 

To further study these compounds and their anti-carcinogenic potential,

researchers induced cancer in control mice, as well as those treated

with GCP, AHCC or a combination of the two. Tumor growth was inhibited

by treatment with GCP and AHCC singly, although combined treatment was

more effective at inhibiting tumor growth and inducing apoptosis.26

 

While the soy isoflavone genistein was shown to have anti-carcinogenic

potential in combination with AHCC, soy and its components may also have

 

protective effects against cancer individually. Soy supplements are

popular with consumers who are treating cancer, as well. NMI noted that

while 7.1 percent of the general population takes soy supplements, 10.9

percent of cancer patients take them.

 

Researchers from the Northern California Cancer Center in Union City

conducted a population-based, case-control study of thyroid cancer in

the San Francisco Bay Area. They interviewed 608 cases and 558 controls

and assessed phytoestrogen consumption via a food-frequency

questionnaire. Consumption of traditional and nontraditional soy-based

foods and alfalfa sprouts was associated with reduced risk of thyroid

cancer. Researchers noted that of the seven phytoestrogenic compounds

examined, daidzein and genistein, as well as the lignan,

secoisolariciresinol, were most strongly associated with risk

reduction.27

 

Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit

determined that the mechanism of action behind the anti-carcinogenic

effects of genistein and daidzein is the isoflavones' ability to prevent

 

oxidative damage. Researchers measured levels of oxidative damage in the

 

blood of six women taking 50 mg/d of isoflavones and six men taking 50

mg of isoflavones twice daily. Supplementation with soy (as Novasoy®,

manufactured by ADM Health in Decatur, Ill.) was found to reduce the

levels of oxidative DNA damage in all subjects.28

 

Animal research conducted at the University of California, Berkeley,

indicated soy may also protect against skin cancer. Investigators

conducted a 19-week study on mice--those given the soy protein, lunasin,

 

showed significantly lower rates of skin cancer than the control group.

Mice in the high-dose group (125 mcg twice a week) had a 70-percent

reduction of malignant tumors.29

 

One negative aspect to soy supplementation is the ongoing concern that

phytoestrogen intake may adversely affect breast cancer patients. In

fact, recent NIH-funded animal research out of the University of

Illinois at Urbana-Champaign indicated that genistein may negate the

effect of tamoxifen, a commonly prescribed pharmaceutical for women with

 

estrogen-dependent breast cancer. In a pre-clinical study, researchers

divided 66 mice (whose ovaries had been removed) into six groups to

monitor the effects of estrogen and various amounts of tamoxifen and

genistein. Before genistein was added to the diet, tamoxifen had stopped

 

tumor growth; however, the addition of genistein resulted in enhanced

growth of estrogen-dependent tumors and increases in estrogen-responsive

 

gene markers.30

 

On a more positive note, soy is currently being studied by researchers

at Ohio State University Comprehensive Cancer Center for its protective

effects against prostate cancer in combination with the carotenoid

lycopene. Lycopene from tomato sauce may reduce the risk of prostate

cancer, according to researchers in Chicago at the University of

Illinois, who advised 32 prostate cancer patients to consume one tomato

sauce-based pasta dish daily for three weeks before prostatectomy.

Levels of oxidative DNA damage and PSA were significantly reduced after

the dietary intervention--28 percent and 17.5 percent, respectively.31

 

While its most popular application is in prostate cancer, lycopene has

also been shown to reduce the risk of lung cancer.

 

Harvard researchers,

who evaluated more than 124,000 male and female cases from the Health

Professionals Follow Up Study and the Nurses Health Study, linked diets

rich in organic tomato-based products to a reduced risk of lung cancer.

 

The researchers noted that those consuming the highest dietary amounts

of lycopene, in addition to mixed carotenoids--

 

alpha-carotene, beta-carotene, lutein and beta-cryptoxanthin--had a 20

percent to 25 percent reduced risk of lung cancer.32

 

Carotenoid intake--beta-carotene, lutein, alpha-carotene and

beta-cryptoxanthin--has been linked with a reduced risk of breast

cancer, as well. Researchers from New York University School of Medicine

compared 270 cases and 270 controls for serum levels of carotenoids.

 

The risk of breast cancer almost doubled among subjects with blood

levels of beta-carotene, lutein and beta-cryptoxanthin at the lowest

quartile, as compared with those at the highest quartile.33

 

Of the carotenoids, lutein is especially popular among cancer patients.

 

According to NMI, 14.7 percent of those taking supplements for cancer

take a lutein supplement compared to 8.6 percent of the general

population. Lutein is linked to a reduced risk of colon cancer,

according to researchers at the University of Utah Medical School.

 

They collected dietary data from 1,993 case subjects with colon cancer

and 2,410 population-based control subjects. Lutein intake from dietary

sources was inversely associated with colon cancer in both men and

women.34

 

Astaxanthin, a carotenoid extract taken from algae, has been studied in

conjunction with other carotenoids--beta-carotene and canthaxanthin--for

 

its protective effects against breast cancer.

 

Researchers at Washington State University in Pullman fed mice either a

control diet with no

carotenoids or one of six treatment diets containing 0.1 percent or 0.4

percent of beta-carotene, astaxanthin or canthaxanthin. Researchers

induced cancer in the mice after three weeks.

 

Plasma concentrations of astaxanthin were greater than beta-carotene or

canthaxanthin, and all

three carotenoids generally decreased mammary tumor volume. However,

astaxanthin was found to dose-dependently reduce mammary tumor growth at

a higher rate than the others.35

 

Astaxanthin exerts anti-tumor activity through " enhancing " immune

responses, according to researchers at the University of Minnesota in

Minneapolis.

 

Investigators fed mice an astaxanthin diet starting at

zero, one and three weeks before inducing tumor growth.

 

The astaxanthin-fed mice had significantly reduced tumor size and weight

 

than control mice when supplementation was started one and three weeks

before tumor inducement.36

 

 

Botanicals

 

An extract derived from the aloe plant is also thought to have

application in chemopreventive medicine.

 

Researchers from the National Institute of Health Sciences in Tokyo

induced pancreatic cancer in

hamsters through four weekly subcutaneous injections, and then the

animals were given zero, 1 percent or 5 percent freeze-dried aloe (Aloe

arborescens) whole-leaf powder for five weeks.

 

At week 54, the

incidences of pancreatic cancers were significantly decreased in both

the 1 percent and 5 percent aloe groups as compared to the control

group.

 

In addition, total lesions were significantly lower in the 5

percent aloe group than the control group. Researchers concluded that

pretreatment with aloe prevented pancreatic cancer.37

 

Similar results were garnered by researchers at Fujita Health University

in Hisai, Japan. They examined the effect of whole-leaf Aloe arborescens

 

(Miller var. natalensis Berger) on induced colorectal cancer in rats.

Rats who were fed 1 percent and 5 percent diets of aloe for nine weeks

exhibited fewer colorectal aberrations compared to the control animals.

 

 

Researchers concluded that aloe may be effective for chemoprevention in

colon cancer, at least in the initiation stage.38

 

Another plant-based compound, the extract from French maritime pine

bark, has shown anticarcinogenic potential in recent research.

Investigators at Loma Linda University School of Medicine in California

conducted in vitro research comparing the response of human breast

cancer cells and normal human mammary cells to apoptosis in the presence

 

of French maritime pine bark extract (as Pycnogenol®, distributed by

Hillside, N.J.-based Natural Health Sciences).

 

Researchers discovered that cell death was significantly higher in the

cancer cells treated with the extract than the untreated cells, and the

extract did not

increase the number of normal cell deaths. Researchers concluded that

the extract selectively induced cell death in human mammary cancer cells

and not in healthy mammary cells.39

 

An extract from the berries of the saw palmetto plant has been studied

for its potential role in cancer--specifically, prostate cancer.

 

Saw palmetto, which is best known for its efficacy at reducing the

symptoms of benign prostatic hyperplasia (BPH), may also be a potential

anti-carcinogen.

 

While research is conflicting, NMI data indicates that

9.4 percent of consumers who have cancer use saw palmetto as compared to

6.7 percent of the general population.

 

Researchers from Boston BioProducts Inc. in Ashland, Mass., conducted in

vitro research on prostatic cell lines, which were treated with a saw

palmetto berry extract.

 

Proliferation of these prostatic cell lines was inhibited to different

degrees when dosed for three days with saw

palmetto. Researchers found that the saw palmetto treatment reduced

Cox-2 expression, which is associated with an increased incidence of

prostate cancer.40

 

While in vitro research is promising, human research has not thus far

indicated that saw palmetto would be helpful against prostate cancer. A

clinical trial conducted at the University of California, Los Angeles,

involving 44 men demonstrated that the supplement did not affect PSA or

prostate volume, although it was seen to be a safe, highly desirable

option for men with moderately symptomatic BPH.41

 

 

 

Grape seed extract, which contains antioxidant compounds called

proanthocyanidins, may also inhibit cancer cell growth.

 

Researchers from Creighton University School of Pharmacy & Allied Health

Professionals in Omaha, Neb., compared the antioxidant capabilities of a

novel IH636 grape seed proanthocyanidin extract both in vitro and in

vivo to vitamins C, E and beta-carotene.

 

Researchers said the grape seed proanthocyanidin extract was highly

bioavailable and provided superior free radical protection.

 

In addition, the extract demonstrated

cytotoxicity toward human breast, lung and gastric cancer cells while

enhancing the growth and viability of normal human gastric mucosal

cells.42

 

Researchers from the University of Nebraska Medical Center in Omaha

conducted in vitro research, comparing the destructive effects of

chemotherapy on Chang liver cells treated with grape seed

proanthocyanidins with untreated cells.

 

The extract decreased the number of cell deaths induced by

chemotherapy, leading researchers to conclude

proanthocyanidin is a potential candidate for lessening the toxic

effects associated with chemotherapeutic agents used to treat cancer.43

 

Similar to proanthocyanidins from grape seeds, dietary

indoles--including indole-3-carbinol (I3C), diindolylmethane, ascorbigen

and gramine--can be extracted from cruciferous vegetables and some forms

of grain.

 

Of the dietary indoles present in nature, I3C and

diindolylmethane are purportedly useful in inhibiting cancer growth,

according to David Parish, chief executive officer of Orem, Utah-based

Designed Nutritional Products, who gave a VendorWorks presentation on

this topic at SupplySide East 2002 in Secaucus, N.J.

 

I3C has been shown to inhibit uterine and breast cancers, as well as

chemical carcinogens, according to Parish. I3C reduces the damage of

many chemical carcinogens by inhibiting damage to DNA and enhancing the

breakdown and excretion of the chemicals, as well as slowing enzyme

activation. I3C has also been shown to inhibit tumor formation in

animals, according to Parish, although it may promote tumor growth if

the tumor is present at the onset of supplementation.

 

Additional animal research has shown that I3C may improve the body's

response to chemotherapy.

 

Diindolylmethane is another dietary indole that is thought to be

anti-carcinogenic.

 

Specifically, it has been shown to promote in vitro

apoptosis of breast cancer cells, according to Parish.

 

 

Essential fatty acids (EFAs), a group of naturally occurring unsaturated

fats, may also have application in cancer prevention. Conjugated

linoleic acid (CLA) has potential for reducing the risk of colorectal

and prostate cancer, according to researchers from Harvard Medical

School. They conducted in vitro research to study the antiproliferative

effects of CLA (as CLA One™, manufactured by PharmaNutrients in Lake

Bluff, Ill.) against the growth of human colorectal and prostate

carcinoma cells. Researchers concluded that novel CLA may prove

effective as a chemopreventive supplement for individuals at risk or

diagnosed with colorectal or prostate cancer.44

 

 

 

Research involving additional EFAs--docosahexaenoic acid (DHA),

eicosapentaenoic acid (EPA) and arachidonic acid (AA)--indicated that

DHA and EPA effectively reduced the risk of skin cancer while AA may

not.

 

Researchers from the University of Minnesota in Austin found that

ingesting omega-3 fatty acids (EPA and DHA) had a protective effect,

while ingesting the omega-6 fatty acid (AA) did not reduce risk of skin

cancer.

 

Authors concluded that the ratio of omega-3s to omega-6s in the

diet is an important factor for health.45

 

A healthy intake is suggested at an approximate ratio of 3-to-1 omega-3s

to omega-6s.

 

There are dozens of diet-derived compounds and botanical options that

have been studied in regard to cancer prevention, although many of them

await human clinical trials.

 

However, the in vitro and animal research

is promising. The future will tell if there are diet-derived or

botanical ingredients that are indisputable cancer prevention tools.

Until then, manufacturers and consumers alike will continue to read the

latest research and buy supplements backed by sound science.

 

A healthy diet accompanied by a consistent exercise regimen is the

surest way to protect against cancer.

 

But because today's world is fast-paced, replete

with fast-food alternatives to healthy eating and rife with

environmental toxins, supplements have become popular for fortifying the

 

immune system and fighting the free radical damage that may cause

cancer.

 

" Reprinted with Permission from the Natural Products Industry Insider.

For more information visit www.naturalproductsinsider.com or call

480-990-1101 ex 1157. "

 

References

 

Crowell JA et al. “Progress in Cancer chemoprevention: Development of

diet-derived chemopreventive agents.” J Nutr 130:467S-471S, 2000.

www.nutrition.org. • Woodson K et al. “Long-term alpha-tocopherol

supplementation is associated with lower serum vascular endothelial

growth factor levels.” Anticancer Res. 22(1A):375-8, 2002.

www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm. • Zhang Y et al.

“Vitamin E succinate inhibits the function of androgen receptor and the

expression of prostate-specific antigen in prostate cancer cells.” PNAS.

 

99(11):7408-13, 2002. www.pnas.org. • Jedrychowski W et al. “Nutrient

intake patterns in gastric and colorectal cancers.” Int J Occup Med

Environ Health. 14(4):391-5, 2001.

www.imp.lodz.pl/eng/ijomh/ijomenx.htm. • Schwenke DC. “Does lack of

tocopherols and tocotrienols put women at increased risk of breast

cancer?” J Nutr Biochem. 13(1):2-20, 2002.

www.elsevier.com/locate/jnutbio. • Nesaretnam K et al. “Tocotrienols

inhibit growth of ZR-75-1 breast cancer cells.” Int J Food Sci Nutr. 51

Suppl:S95-103, 2000. www.medbioworld.com/bio/journals/food.html. • Mayne

 

ST et al. “Nutrient intake and risk of subtypes of esophageal and

gastric cancer.” Cancer Epidemiol Biomarkers Prev. 10:1055-62, 2001.

http://cebp.aacrjournals.org. • Crane FL. “Biochemical functions of

coenzyme Q10.” J Am Coll Nutr. 20(6):591-8, 2001.

www.am-coll-nutr.org/jacn/jacn.htm. • Portakal O et al. “Coenzyme Q10

concentrations and antioxidant status in tissues of breast cancer

patients.” Clin Biochem. 33(4):279-84, 2000.

www.elsevier.nl/inca/publications/store/5/2/5/4/6/3. • Thompson JR et

al. “Maternal folate supplementation in pregnancy and protection against

 

acute lymphoblastic leukaemia in childhood: a case-control study.”

Lancet. 358(9297):1935-40, 2001. www.thelancet.com. • Xiao SD et al.

“Interventional study of high dose folic acid in gastric carcinogenesis

in beagles.” Gut. 50(1):61-4, 2002. http://gut.bmjjournals.com. • Terry

P et al. “Dietary intake of folic acid and colorectal cancer risk in a

cohort of women.” Int J Cancer. 97(6):864-7, 2002.

www3.interscience.wiley.com. • Selhub J. “Folate, vitamin B12 and

vitamin B6 and one carbon metabolism.” J Nutr Health Aging. 6(1):39-42,

2002. www.springerpub.com. • Komatsu SI et al. “Vitamin B6-supplemented

diets compared with a low vitamin B6 diet suppress azoxymethane-induced

colon tumorigenesis in mice by reducing cell proliferation.” J Nutr.

131(:2204-7, 2001. www.nutrition.org. • Mangelsdorf DJ et al. “Vitamin

D receptor as an intestinal bile acid sensor.” Science.

296(5571):1313-6, 2002. www.sciencemag.org. • Brooks JD et al. “Plasma

selenium level before diagnosis and the risk of prostate cancer

development.” J Urol. 166(6):2034-38, 2001. www.jurology.com. • Mark SD

et al. “Prospective study of serum selenium levels and incident

esophageal and gastric cancers.” J Natl Cancer Inst. 92(21):1753-63,

2000. http://jncicancerspectrum.oupjournals.org/jnci.• Nakaji S et al.

“Relationship between mineral and trace element concentrations in

drinking water and gastric cancer mortality in Japan.” Nutr Cancer.

40(2):99-102, 2001. www.erlbaum.com. • Kazmierski KJ et al. “Serum zinc,

 

chromium, and iron concentrations in dogs with lymphoma and

osteosarcoma.” J Vet Intern Med. 15(6):585-8, 2001. • Wu K et al.

“Calcium Intake and Risk of Colon Cancer in Women and Men.” J Nat Cancer

 

Inst. 94(6):437-46, 2002.

http://jncicancerspectrum.oupjournals.org/jnci. Chan JM et al. “Dairy

products, calcium, and prostate cancer risk in the Physicians' Health

Study.” AJCN. 74(4):549-54, 2001. www.ajcn.org. • Fullerton SA et al.

“Induction of apoptosis in human prostatic cancer cells with beta-glucan

 

(Maitake mushroom polysaccharide).” Mol Urol. 4(1):7-13, 2000.

www.liebertpub.com/mou/default1.asp. • Rodrigues RC et al.

“Antimutagenic effects of the mushroom Agaricus blazei Murrill extracts

on V79 cells.” Gen Tox Env Mutagen. 496(1-2):5-13, 2001.

www.elsevier.com/locate/mutres. • Mizuno M et al. “Polysaccharides from

Agaricus blazei stimulate Lymphocyte T-cell subsets in mice.” Biosci

Biotechnol Biochem. 62(3):434-7, 1998. www.jsbba.or.jp/bbindexj.html. •

Lu H et al. “Prevention of the development of preneoplastic lesions,

aberrant crypt foci, by a water-soluble extract from cultured medium of

Ganoderma lucidum (Rei-shi) mycelia in male F344 rats.” Oncol Rep.

8(6):1341-5, 2001. • Amino Up Chemical Co. “Synergistic anti-tumor

effects of mushroom polysaccharides (AHCC) and aglycone isoflavones

(GCP) on prostate and other cancers.” American Association for Cancer

Research (AACR) conference, March 26-27, 2001. www.aacr.org. • Horn-Ross

 

et al. “Phytoestrogens and thyroid cancer risk: the san Francisco bay

area thyroid cancer study.” Cancer Epidemiol Biomarkers Prev.

11(1):43-9, 2002. • Djuric Z et al. “Effect of soy isoflavone

supplementation on markers of oxidative stress in men and women.” Cancer

 

Lett. 172(1):1-6, 2001. www.elsevier.com/locate/canlet. • Galvez AF et

al. “Chemopreventive property of a soybean peptide (lunasin) that binds

to deacetylated histones and inhibits acetylation.” Cancer Res.

61(20):7473-8, 2001. http://cancerres.aacrjournals.org. • Ju YH et al.

“Dietary Genistein Negates the Inhibitory Effect of Tamoxifen on Growth

of Estrogen-dependent Human Breast Cancer (MCF-7) Cells Implanted in

Athymic Mice.” Cancer Res. 62(9):2474-77, 2002.

http://cancerres.aacrjournals.org. • Chen L et al. “Oxidative DNA Damage

 

in Prostate Cancer Patients Consuming Tomato Sauce-Based Entrees as a

Whole-Food Intervention.” J Nat Cancer Inst. 93(24):1872-9, 2001.

http://jncicancerspectrum.oupjournals.org. • Michaud DS. “Intake of

specific carotenoids and risk of lung cancer in 2 prospective US

cohorts.” AJCN. 72(4):990-7, 2000. www.ajcn.org. • Toniolo P et al.

“Serum carotenoids and breast cancer.” Am J Epidemiol. 153(12):1142-7,

2001. www.aje.oupjournals.org. • Slattery ML et al. “Carotenoids and

colon cancer.” AJCN. 71(2):575-82, 2000. www.ajcn.org. • Chew BP et al.

“A comparison of the anticancer activities of dietary beta-carotene,

canthaxanthin and astaxanthin in mice in vivo.” Anticancer Res.

19(3A):1849-53, 1999.

www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm. •yonouchi H et al.

“Antitumor activity of astaxanthin and its mode of action.” Nutr Cancer.

 

36(1):59-65, 2000. www.erlbaum.com. • Furukawa F et al. “Chemopreventive

 

effects of Aloe arborescens on N-nitrosobis(2-oxopropyl)amine-induced

pancreatic carcinogenesis in hamsters.” Cancer Lett. 178(2):117-22,

2002. www.elsevier.com/locate/canlet. •Shimpo K et al. “Inhibition of

azoxymethane-induced aberrant crypt foci formation in rat colorectum by

whole leaf Aloe arborescens Miller var. natalensis Berger.” Phytother

Res. 15(:705-11, 2001.

www3.interscience.wiley.com/cgi-bin/jtoc?ID=12567. • Huynh HT, Teel RW.

“Selective induction of apoptosis in human mammary cancer cells (MCF-7)

by pycnogenol.” Anticancer Res. 20(4):2417-20, 2000.

www.geocities.com/Athens/Rhodes/

 

8729/iiar/iiar.htm. • Goldmann WH et al. “Saw palmetto berry extract

inhibits cell growth and Cox-2 expression in prostatic cancer cells.”

Cell Biol Int. 25(11):1117-24, 2001. www.apnet.com. •Marks LS et al.

“Effects of a saw palmetto herbal blend in men with symptomatic benign

prostatic hyperplasia.” J Urol. 163(5):1451-6, 2000. www.jurology.com. •

 

Bagchi D et al. “Free radicals and grape seed proanthocyanidin extract:

importance in human health and disease prevention.” Toxicology.

148(2-3):187-97, 2000. www.elsevier.com/inca/

 

publications/store/5/0/5/5/1/8. •Joshi SS et al. “Chemopreventive

effects of grape seed proanthocyanidin extract on Chang liver cells.”

Toxicology. 155(1-3):83-90, 2000.

www.elsevier.com/inca/publications/store/5/0/5/5/1/8. • Palombo JD et

al. “The antiproliferative effects of biologically active isomers of

conjugated linoleic acid on human colorectal and prostatic cancer

cells.” Cancer Lett. 177:163-72, 2002. www.elsevier.com/locate/canlet. •

 

Liu G et al. “Omega 3 but not omega 6 fatty acids inhibit AP-1 activity

and cell transformation in JB6 cells.” PNAS. 98(13):7510-5, 2001.

www.pnas.org.

 

" Reprinted with Permission from the Natural Products Industry Insider.

For more information visit www.naturalproductsinsider.com or call

480-990-1101 ex 1157. "

_________________

JoAnn Guest

mrsjo-

DietaryTi-

www.geocities.com/mrsjoguest/Genes

 

 

 

 

AIM Barleygreen

" Wisdom of the Past, Food of the Future "

 

http://www.geocities.com/mrsjoguest/Diets.html